pegvaliase pegvaliase pegvaliase, sold under the brand name palynziq, is a medication for the treatment of the genetic disease phenylketonuria. chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels. pegvaliaseclinical datapronunciationpeg val' i ase trade namespalynziqother namespegvaliase-pqpz; peg-pal; ravpal-pegahfs/drugs.commonographmedlineplusa618057license data us dailymed: pegvaliase pregnancycategory au: d routes ofadministrationsubcutaneousatc codea16ab19 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only / schedule d us: ℞-only eu: rx-only identifiers iupac name (2s)-2-amino-6-hexanoic acid cas number1585984-95-7pubchem cid86278362drugbankdb12839chemspider58172730uniin6uah27euvkeggd11077chemical and physical dataformulac15h30n2o5molar mass318.414 g·mol−13d model (jsmol)interactive image smiles coccocccccc(=o)ncccc(n)c(o)=o inchi inchi=1s/c15h30n2o5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13h,2-12,16h2,1h3,(h,17,18)(h,19,20)/t13-/m0/s1key:npocdvaoukodsq-zdusscgksa-n it was approved by the food and drug administration for use in the united states in 2018. the u.s. food and drug administration (fda) considers it to be a first-in-class medication.